Moderna (MRNA) announced that its mRNA flu vaccine received a unanimous positive recommendation from the FDA’s advisory committee, a key step toward eventual regulatory approval and commercial launch. The endorsement follows the company’s broader push to repurpose its pandemic‑era mRNA platform for seasonal influenza and other infectious diseases.

Axsome Therapeutics (AXSM) meanwhile reported that the U.S. Food and Drug Administration approved a new indication targeting a common, hard‑to‑treat symptom in Alzheimer’s disease, adding to its existing CNS portfolio that includes AUVELITY for depression, SUNOSI for narcolepsy and SYMBRAVO.

Financially, both companies posted sizable losses in fiscal 2025. Moderna’s revenue fell to about $1.9 billion, a 39.2% drop from the prior year, and the firm recorded a net loss of roughly $2.8 billion, driving its net margin to negative 145.2%. Axsome’s revenue rose to $638.5 million, up 65.5% year‑over‑year, but it still posted a net loss of $183.2 million, leaving its net margin at negative 28.7%.

Moderna’s balance sheet shows a low debt‑to‑equity ratio of 0.2× and a strong current ratio of about 3.3×, indicating ample liquidity despite the losses. Axsome’s debt‑to‑equity stood at 2.7×, with a current ratio of 1.6×, reflecting higher leverage as it scales its commercial operations.

Employee counts illustrate the firms’ differing scales. By early 2026, Axsome employed roughly 925 staff, while Moderna plans to trim its workforce to under 5,000 as it transitions from pandemic‑driven demand to a broader mRNA pipeline.

Both companies face distinct risk profiles. Axsome’s outlook hinges on the commercial success of a handful of CNS products and ongoing patent litigation with generic manufacturers such as Apotex. Moderna confronts intense competition in vaccines and oncology from peers like Pfizer, GSK and Sanofi, as well as operational challenges tied to mRNA manufacturing and cold‑chain logistics.

Analysts note that Moderna’s platform offers a “universal medicine‑making engine” that can be re‑tooled for a wide range of diseases, a potential upside that outweighs its short‑term revenue dip. Axsome’s rapid commercial rollout and recent FDA approval suggest momentum, but its narrow cash runway leaves little margin for error.